Evaluating Clinical Efficacy of I-DXd (Anti-B7-H3 ADC) in SLCL & Solid Tumors
- Introducing I-DXd as a B7-H3 directed ADC which has demonstrated efficacy in the Ph1 IDeate-PanTumor01 trial in SCLC and other solid tumor indications
- Outlining interim results from the Ph2 IDeate-Lung01 trial dose optimization stage demonstrated ORR > 50% at the 12 mg/kg dose expansion
- Understanding primary analysis results from the IDeate-Lung01 trial in 2L+ SCLC